ERBB2 and breast carcinoma: Indeed, even though it has been demonstrated that anti-HER2 therapies increase chemo-sensitivity, and despite the fact that combined chemotherapy and anti-HER2 therapy have largely improved HER2-positive breast cancer prognosis, resistances to these treatments exist.